## PART B - FÉE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

**Mail Stop ISSUE FEE** Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

(703) 746-4000 or Fax

	INSTRUCTIONS. This for appropriate. All further indicated unless corrected maintenance fee notification	orm sould be used for transport the spondence including the below or directed otherwisens.	smitting the ISSI Patent, advance of in Block 1, by (	UE FEE and rders and not a) specifying	PUBLICATION FEE (if requification of maintenance fees a new correspondence address	nired). Blocks 1 through 5 swill be mailed to the current; and/or (b) indicating a sep	should be completed where t correspondence address as arate "FEE ADDRESS" for
		CE ADDRESS (Note: Use Block 1 for 590 07/01/2005	any change of address)	Note: A certificate of Fee(s) Transmittal. The papers. Each addition have its own certification.	Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.		
TERESA STANEK REA BURNS, DOANE, SWECKER AND MATHIS, L.L.P P.O. BOX 1404 ALEXANDRIA, VA 22313-1404					Certificate of Mailing or Transmission  I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (703) 746-4000, on the date indicated below.		
10/0	04/2005 HALI22 00000						(Depositor's name)
	FC:1501	1400.00 OP					(Signature)
	APPLICATION NO.	FILING DATE	FIRST NAMED IN		D INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/252,691	02/18/1999	KEITH G WEI		/EINSTOCK	107196.135	4791
	TITLE OF INVENTION: THERAPEUTICS	: NUCLEIC ACID AND	AMINO ACID	SEQUENCE	ES RELATING TO ENTER	OBACTER CLOACAE FO	OR DIAGNOSTICS AND
	APPLN. TYPE	SMALL ENTITY	ISSUE F	EE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
	nonprovisional YES \$\frac{\$700}{}		+#1400°° so		\$700	10/03/2005	
	EXAMINER		ART UNIT		CLASS-SUBCLASS	7	
	PORTNER, VIRGINIA ALLEN		1645		536-024100	•	
	1. Change of correspondence address or indication of "Fee Addre CFR 1.363).  Change of correspondence address (or Change of Correspondence address form PTO/SB/122) attached.  "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Cunumber is required.			2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.			
-	3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)						
1	PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.						
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)					UNTRY)		
	Genome Therapeutics Corporation Waltham, MA						
	Please check the appropriate assignee category or categories (will not be printed on the patent):						
	4a. The following fee(s) are enclosed:  4b. Payment of Fee(s):						
				A check in the amount of the fee(s) is enclosed.			
				Payment by credit card. Form PTO-2038 is attached.			
	Advance Order - # of Copies			The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number $02-4800$ (enclose an extra copy of this form).			
		(from status indicated above MALL ENTITY status. See			ant is no longer claiming SMA		-

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademant Office.

Authorized Signature

September 30, 2005

Typed or printed name

Christopher L. North, Ph.D.

Registration No.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAIL STOP ISSUE FEE

Keith G. Weinstock et al.

Confirmation No.: 4791

Application No.: 09/252,691

Filing Date:

February 18, 1999

Title: NUCLEIC ACID AND AMINO ACID SEQUENCE RELATING TO ENTEROBGACTER CLOACAE FOR

DIAGNOSTICS AND THERAPEUTICS

## PAYMENT OF ISSUE FEE AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT FOR ANY DEFICIENCY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Attached is an Issue Fee Transmittal form (form PTOL-85). The Director is hereby authorized to charge any fees under 37 C.F.R. §§ 1.18, 1.19, and 1.21 that may be required by the attached Issue Fee Transmittal Form, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

**BUCHANAN INGERSOLL PC** 

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: September 30, 2005

Βv

Christopher L. North, Ph.D.

Registration No. 50,433